Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Recommendation of “Moderate Buy” by Brokerages
Silence Therapeutics (NASDAQ:SLN) versus Avalo Therapeutics (NASDAQ:AVTX) Head-To-Head Comparison
Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Hold” from Brokerages
Silence Therapeutics Announces Leadership Changes
Silence Therapeutics: Divesiran Targets High-Burden PV
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Tonix Pharmaceuticals (NASDAQ:TNXP) versus Silence Therapeutics (NASDAQ:SLN) Critical Survey
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'
Silence: Additional siRNA Drug Data Leads To Next Stages Of Development
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
The 3 Best Gene Editing Stocks to Buy in August 2024
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
7 Biotech Stocks Ready to Ride the Sector's Resurgence
Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)